We speak with Lauren Taus who is the Founder of INBodied Life, who's focus is on integrating modern science and ancient wisdom to support transformation.
Similar Posts
MindMed: What Does The Future Hold? ( MMED/ MNMD )
Hey guys! Today, we’ll cover Part 2 of our discussion on MindMed’s (MMED / MNMD / MMQ) conference call.
In the previous episode, we talked about the progress MindMed has made up until this point, MindMed’s mission, talent Acquisition, and the progress of their clinical trials.
In today’s episode, we will take a more futuristic approach and examine the future plans discussed in MindMed’s Q1 conference call. We will cover topics such as:
A. Where is MindMed going?
B. What is MindMed 2.0?
C. What will MindMed in 3 years time look like as compared to now?
Over the next several years, we expect 4 transformations to occur.
1. MindMed’s transition to a tech company, from a pharmaceuticals company;
2. The shift from classic psychedelics like LSD to “next generation” patent protected substances;
3. Reorientation away from one size fits all medical solutions towards personalized medicine;
4. Finding Partnerships with major pharmaceutical companies.
Timestamps:
0:00 – Intro
2:16 – MindMed transitioning to a tech company
7:14 -Next-gen shift
12:11 – Personalized medicine
13:59 – Partnerships
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #MNMD #MindMedstock
Spotlight on Cannara Biotech with Nicholas Sosiak
In this episode, David Flores sits down with Cannara CFO Nicholas Sosiak, to discuss the Company’s future goals and to spotlight what differentiates Cannara from other companies in the cannabis space.
Interview with Joe Moore, Founder & CEO of Psychedelics Today
In this episode, Joe discusses the current landscape of the industry, his thoughts on its general direction, and why we need to defund the DEA to really progress the movement overall.
UFC Explores Psychedelic Therapy for Brain-Injured Fighters
The UFC (Ultimate Fighting Championship) is working with industry leaders to better understand brain trauma-related problems the combat sport causes athletes. As part of that effort, the organization is taking a long, hard look at psychedelic therapies as possible treatments.
Psychedelic Business Roundup- Key Psychedelic Industry Leader Joins The NASDAQ
May 12, 2021- This week’s Psychedelic Business News Round Up’s…
Psychedelic Stocks in the Short-Term: Expectations, Catalysts, Risks and Reward
When it comes to investing in psychedelic stocks such as MindMed (MNMD, MMED), Compass Pathways (CMPS), atai Life Sciences (ATAI), Cybin (CYBN) and more, even if we have a solid long term thesis, the short term is very volatile.
To sign up for the Psychedelic Stock Tips Newsletter, follow this link and scroll to the bottom of the page: https://psychedelicspotlight.com/about/
Follow us on Twitter:
@Psy_Invest
@psy_holy
@PsycSpotlight
Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight
To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/
PS: THIS IS NOT INVESTING ADVICE, JUST MY OPINION.
In this video, I will discuss what to look out for, both the positives and the negatives, in the coming months. What are the catalysts? What are the risks?
The main thing to understand, is that the market cares more about short term profit than it does long term indicators. Right now, we are seeing psychedelic medicine clinical trials showing fantastic results, but we should not expect the market to react until we are closer to commercialization.
There are also many macro risks to be aware of, and general all around volatility. But we need to remember, short term swings do not affect the long-term thesis.
Links:
Awakn Phase 2 Ketamine Therapy for Alcohol Use Disorder:
https://psychedelicspotlight.com/ketamine-trial-alcohol-use-disorder-promising-results-awakn-life-sciences/
MAPS Phase 3 MDMD for PTSD Trial
https://psychedelicspotlight.com/first-phase-3-trial-mdma-assisted-therapy-ptsd/
Compass Pathways Phase 2b Psilocybin for Depression Trial
https://psychedelicspotlight.com/compass-pathways-largest-psilocybin-therapy-trial-ever-depressive-symptoms-rapidly-reduce/
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#PsychedelicStocks #MindMed #Cybin